{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:57:53Z","timestamp":1790690273348,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell products are currently approved by the FDA, with others in clinical trials. Additional agents in development include bispecific antibodies and antibody drug conjugates. Combinations of targeted therapies should lead to further improvement in the outcome of patients with B-cell malignancies.<\/jats:p>","DOI":"10.1038\/s41408-021-00456-w","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T21:02:37Z","timestamp":1617656557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Diffuse large B-cell lymphoma: new targets and novel therapies"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6246-4308","authenticated-orcid":false,"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-9393","authenticated-orcid":false,"given":"Grzegorz","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"456_CR1","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","volume":"16","author":"JO Armitage","year":"1998","unstructured":"Armitage, J. O. & Weisenburger, D. D. New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. J. Clin. Oncol. 16, 2780\u20132795 (1998).","journal-title":"J. Clin. Oncol."},{"key":"456_CR2","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier, P. et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J. Clin. Oncol. 23, 4117\u20134126 (2005).","journal-title":"J. Clin. Oncol."},{"key":"456_CR3","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 130, 1800\u20131808 (2017).","journal-title":"Blood."},{"key":"456_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn, L. H. et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 38, 155\u2013165 (2020).","journal-title":"J. Clin. Oncol."},{"key":"456_CR5","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda, N. et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 7, e511\u2013e522 (2020).","journal-title":"Lancet Haematol."},{"key":"456_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles, G. et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 21, 978\u2013988 (2020).","journal-title":"Lancet Oncol."},{"key":"456_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"456_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"456_CR9","doi-asserted-by":"publisher","first-page":"abstr. 401","DOI":"10.1182\/blood.2019000950","volume":"136","author":"AJ Olszewski","year":"2020","unstructured":"Olszewski, A. J. et al. Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma. Blood. 136, abstr. 401 (2020).","journal-title":"Blood."},{"key":"456_CR10","first-page":"abstr. 403","volume":"136","author":"M Hutchings","year":"2020","unstructured":"Hutchings, M. et al. Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma. Blood. 136, abstr. 403 (2020).","journal-title":"Blood."},{"key":"456_CR11","first-page":"abstr. 402","volume":"136","author":"M Hutchings","year":"2020","unstructured":"Hutchings, M. et al. Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed\/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy:updated dose escalationd data. Blood. 136, abstr. 402 (2020).","journal-title":"Blood."},{"key":"456_CR12","doi-asserted-by":"publisher","first-page":"abstr. 400","DOI":"10.1182\/blood-2020-136659","volume":"136","author":"R Bannerji","year":"2020","unstructured":"Bannerji, R. et al. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy. Blood. 136, abstr. 400 (2020).","journal-title":"Blood."},{"key":"456_CR13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","volume":"16","author":"MC Palanca-Wessels","year":"2015","unstructured":"Palanca-Wessels, M. C. et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 16, 704\u2013715 (2015).","journal-title":"Lancet Oncol."},{"key":"456_CR14","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","volume":"129","author":"J Kuruvilla","year":"2017","unstructured":"Kuruvilla, J. et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 129, 3175\u20133183 (2017).","journal-title":"Blood."},{"key":"456_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30290-8","volume":"7","author":"SD Smith","year":"2020","unstructured":"Smith, S. D. & Gopal, A. K. Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact. Lancet Haematol. 7, e707 (2020).","journal-title":"Lancet Haematol."},{"key":"456_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/1074-7613(95)90157-4","volume":"3","author":"P Engel","year":"1995","unstructured":"Engel, P. et al. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 3, 39\u201350 (1995).","journal-title":"Immunity."},{"key":"456_CR17","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1158\/1078-0432.CCR-19-0711","volume":"25","author":"BS Kahl","year":"2019","unstructured":"Kahl, B. S. et al. A phase I study of ADCT-402 (Loncastuximab Tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed\/refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 25, 6986\u20136994 (2019).","journal-title":"Clin. Cancer Res."},{"key":"456_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 396, 839\u2013852 (2020).","journal-title":"Lancet."},{"key":"456_CR19","doi-asserted-by":"crossref","unstructured":"Hamadani, M. et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood (2020). Online ahead of print.","DOI":"10.1182\/blood.2020007512"},{"key":"456_CR20","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1182\/blood-2014-08-593269","volume":"124","author":"JA Woyach","year":"2014","unstructured":"Woyach, J. A. et al. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 124, 3553\u20133560 (2014).","journal-title":"Blood."},{"key":"456_CR21","doi-asserted-by":"publisher","first-page":"abstr. 1754","DOI":"10.1182\/blood-2019-128388","volume":"134","author":"PB Staber","year":"2019","unstructured":"Staber, P. B. et al. Primary analysis of anti-CD19 tafasitamab (MOR208) treatment in combination with idelalisib or venetoclax in R\/R CLL patients who failed prior BTK inhibitor therapy (COSMOS Trial). Blood. 134, abstr. 1754 (2019).","journal-title":"Blood."},{"key":"456_CR22","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","volume":"29","author":"W Jurczak","year":"2018","unstructured":"Jurczak, W. et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. Ann. Oncol. 29, 1266\u20131272 (2018).","journal-title":"Ann. Oncol."},{"key":"456_CR23","doi-asserted-by":"crossref","unstructured":"Salles, G. et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. EHA Library. abstr. EP1201 (2020).","DOI":"10.1016\/S2152-2650(20)30877-6"},{"key":"456_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.clml.2020.03.009","volume":"20","author":"BD Cheson","year":"2020","unstructured":"Cheson, B. D., Morschhauser, F. & Martin, P. Management of adverse events from the combination of rituximab and lenalidomide in the treatment of patients with follicular and low-grade non-Hodgkin lymphoma. Clin. Lymphoma Myeloma Leuk. 20, 563\u2013571 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"456_CR25","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1200\/JCO.2020.38.15_suppl.8020","volume":"38","author":"GS Nowakowski","year":"2020","unstructured":"Nowakowski, G. S. et al. RE-MIND study: a propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real world data) in transplant-ineligible patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). J. Clin. Oncol. 38, 8020 (2020).","journal-title":"J. Clin. Oncol."},{"key":"456_CR26","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/leu.2013.95","volume":"27","author":"M Wang","year":"2013","unstructured":"Wang, M. et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 27, 1902\u20131909 (2013).","journal-title":"Leukemia."},{"key":"456_CR27","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","volume":"11","author":"PL Zinzani","year":"2011","unstructured":"Zinzani, P. L. et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin. Lymphoma Myeloma Leuk. 11, 462\u2013466 (2011).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"456_CR28","doi-asserted-by":"publisher","first-page":"abstr. 405","DOI":"10.1182\/blood-2020-134449","volume":"136","author":"SS Neelapu","year":"2020","unstructured":"Neelapu, S. S. et al. Interim analysis of ZUMA-12: a phase 2 study of axicaptagene ciloleucel (Axi-Cel) as first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL). Blood. 136, abstr. 405 (2020).","journal-title":"Blood."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00456-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00456-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00456-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:43:10Z","timestamp":1669909390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00456-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00456-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"30 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.D.C.\u2014Advisory boards\/consulting\u2014Morphosys, Karyopharm, BMS\/Celgene, Kite, Epizyme, Beigene, Symbio, TG Therapeutics; G.N.\u2014Celgene\/BMS, Morphosys, Curis, Seattle Genetics, Kymera, Kite, Ryvu; G.S.\u2014Morphosys, Abbvie, Autolus, Beigene, BMS\/Celgene, Genmab, Roche, Janssen, Debiopharm, Milteniy, Novartis, Velosbio.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"68"}}